Anpac Bio-Medical Science Co., Ltd.

109 articles about Anpac Bio-Medical Science Co., Ltd.

• Fresh2 Group Ltd. Announces US$4.4 Million Private Placement

  6/5/2023

  Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. announced that on June 2, 2023, it completed a private placement of 22,000,000 class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares for US$4.4 million.

• AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering

  4/7/2023

  AnPac Bio-Medical Science Co., Ltd. announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs.

• AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.

  4/3/2023

  AnPac Bio-Medical Science Co., Ltd. announced that on March 31, 2023, the Company entered into an asset purchase agreement with Easy Hundred Inc., a U.S.-based e-commerce company in the foodservice industry, through which the Company will acquire certain fixed assets of Easy Hundred and Easy Hundred's intellectual property relating to ez100, 2Supply and 100WAY.

• AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering

  4/1/2023

  AnPac Bio-Medical Science Co., Ltd. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.

• AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023

  3/23/2023

  AnPac Bio-Medical Science Co., Ltd. announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel ("Panel") of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company's request for continued listing on The Capital Market has been granted.

• AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract

  3/7/2023

  AnPac Bio-Medical Science Co., Ltd. announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio's Model AP9080 cancer detection devices.

• AnPac Bio-Medical Science Announces US$5 Million Private Placement

  3/6/2023

  announced that on March 2023, the Company has entered into definitive investment agreements with certain accredited investors in a private placement transaction, pursuant to which the investors agreed to subscribe for and purchase, and the Company agreed to issue and sell an aggregate of 16,666,665 newly issued Class A ordinary shares of the Company.

• AnPac Bio Announces Positive Results from its Multi-Year and Multi-Cancer Test Follow-Up Study

  2/22/2023

  AnPac Bio-Medical Science Co., Ltd. announced up-dated positive results from its first major multi-year and multi-cancer test follow-up study.

• AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

  2/15/2023

  AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC) announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises.

• AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.

  2/13/2023

  AnPac Bio-Medical Science Co., Ltd. announced that on February 12, 2023, the Company, through its subsidiary Foodbase Group Inc., entered into a definitive equity purchase agreement to acquire a group of affiliated companies, SLV Windfall Group LLC, Windfall SLV Development LLC and SLV Windfall Management, LLC, which are engaged in developing, marketing and selling real estate in Savannah Lakes Village, a planned community located in McCormick County, South Carolina.

• AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements

  1/25/2023

  AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC) announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors.

• AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022

  12/19/2022

  AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced its unaudited financial results for the six months ended June 30, 2022.

• AnPac Announces the Plan of US$5,000,000 Private Placement

  12/5/2022

  AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company has reached a mutual understanding with nine investors.

• AnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food Market

  12/5/2022

  AnPac Bio-Medical Science Co., Ltd. announced that the Company has formed a wholly-owned subsidiary Fresh2 Technology Inc in the State of Delaware on October 4, 2022 in order to establish the company's new product line of business-to-business food trade and delivery platform for local restaurants and supermarkets, a combination of the China’s food distribution strategies and North America’s growing Asian food market.

• AnPac Announces Regaining Compliance with Nasdaq Listing Requirement

  11/30/2022

  AnPac Bio-Medical Science Co., Ltd. today announced that the company has been notified by the Office of the General Counsel of The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1 per share bid price requirement of Listed Securities required for continued listing as set forth in Listing Rule 5450(a)(1).

• AnPac Bio Announces Changes to the Board of Directors

  11/10/2022

  AnPac Bio-Medical Science Co., Ltd. today announced the resignation of Yuyang Cui as (i) the Co-Chair of the board of directors (the “Board”), and (ii) the Co-Chief Executive Officer, effective from November 7, 2022, and the resignation of Jiawen Kang from the position of (i) a director of the Board, (ii) a member of the audit committee, and (iii) a member of the nominating and corporate governance committee, effective from November 4, 2022.

• AnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022

  11/4/2022

  AnPac Bio-Medical Science Co., Ltd. announced that on October 31, 2022, the Company has been notified by the Nasdaq Hearings Panel of the Listing Qualifications Department of The Nasdaq Stock Market LLC.

• AnPac Bio Announces Plan to Implement ADS Ratio Change

  10/18/2022

  AnPac Bio-Medical Science Co., Ltd. today announced that it plans to change the ratio of the Company’s American Depositary Shares (“ADSs”) to its Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.

• AnPac Bio Announces Board and Management Changes

  10/3/2022

  AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced changes to its board composition and management team.

• AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million

  9/27/2022

  AnPac Bio-Medical Science Co., Ltd. announced that on September 26, 2022, the Company and a group of nine institutional and individual investors have signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 Million.